MA54091A - Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr - Google Patents

Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr

Info

Publication number
MA54091A
MA54091A MA054091A MA54091A MA54091A MA 54091 A MA54091 A MA 54091A MA 054091 A MA054091 A MA 054091A MA 54091 A MA54091 A MA 54091A MA 54091 A MA54091 A MA 54091A
Authority
MA
Morocco
Prior art keywords
compounds
methods
pharmaceutical compositions
atr inhibitors
kinase atr
Prior art date
Application number
MA054091A
Other languages
English (en)
Inventor
Abbas Abdoli
Cameron Black
Sheldon N Crane
Stéphane Dorich
Lee Fader
Paul Jones
Cyrus M Lacbay
Stéphanie Lanoix
Audrey Picard
Miguel St-Onge
Jean-François Truchon
Vouy Linh Truong
Original Assignee
Repare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repare Therapeutics Inc filed Critical Repare Therapeutics Inc
Publication of MA54091A publication Critical patent/MA54091A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA054091A 2018-10-30 2019-10-30 Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr MA54091A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752873P 2018-10-30 2018-10-30
US201962877177P 2019-07-22 2019-07-22

Publications (1)

Publication Number Publication Date
MA54091A true MA54091A (fr) 2021-09-15

Family

ID=70461742

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054091A MA54091A (fr) 2018-10-30 2019-10-30 Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr

Country Status (16)

Country Link
US (1) US20210277002A1 (fr)
EP (1) EP3873905A4 (fr)
JP (1) JP2022510501A (fr)
KR (1) KR20210097124A (fr)
CN (1) CN113454080A (fr)
AU (1) AU2019373416A1 (fr)
BR (1) BR112021008336A2 (fr)
CA (1) CA3118218A1 (fr)
CR (1) CR20210281A (fr)
EC (1) ECSP21038390A (fr)
IL (1) IL282801A (fr)
MA (1) MA54091A (fr)
MX (1) MX2021005012A (fr)
PH (1) PH12021550992A1 (fr)
SG (1) SG11202104460UA (fr)
WO (1) WO2020087170A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021012049A1 (fr) * 2019-07-22 2021-01-28 Repare Therapeutics Inc. Dérivés 2-morpholinopyridine substitués utilisés en tant qu'inhibiteurs de kinases atr
KR20220128350A (ko) * 2019-12-11 2022-09-20 리페어 세라퓨틱스 인크. Parp 억제제와 조합되는 atr 억제제의 용도
TW202214642A (zh) * 2020-07-02 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 咪唑并嘧啶類衍生物、其製備方法及其在醫藥上的應用
EP4192836A1 (fr) * 2020-08-07 2023-06-14 Antengene Discovery Limited Inhibiteurs d'atr et leurs utilisations
US20240043419A1 (en) * 2020-09-27 2024-02-08 Medshine Discovery Inc. Class of 1,7-naphthyridine compounds and application thereof
BR112023022481A2 (pt) * 2021-04-28 2024-02-15 Repare Therapeutics Inc Métodos de tratamento de cânceres com mutação de perda de função bialélica ou de superexpressão gênica
IL309388A (en) * 2021-06-16 2024-02-01 Repare Therapeutics Inc Combining ATR inhibitors and PARP inhibitors for cancer treatment
CN115677730A (zh) 2021-07-27 2023-02-03 上海辉启生物医药科技有限公司 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
TWI831325B (zh) * 2021-08-11 2024-02-01 大陸商微境生物醫藥科技(上海)有限公司 作為atr抑制劑的萘啶衍生物及其製備方法
WO2023109883A1 (fr) * 2021-12-15 2023-06-22 上海翊石医药科技有限公司 Composés substitués par un hétérocycle aromatique, procédé de préparation associé et leur utilisation
WO2023193114A1 (fr) * 2022-04-07 2023-10-12 Repare Therapeutics Inc. Procédés d'utilisation d'inhibiteurs d'atr

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2966075B1 (fr) * 2009-12-31 2019-02-27 Hutchison Medipharma Limited Certains triazolopyridines, leurs compositions et leurs utilisations dans le traitement du cancer
WO2013039988A1 (fr) * 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
WO2013067302A1 (fr) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Méthode de traitement
US8906910B2 (en) * 2011-12-20 2014-12-09 Glaxosmithkline Llc Imidazopyridine derivatives as PI3 kinase
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
KR20240017991A (ko) * 2015-04-29 2024-02-08 라포 테라퓨틱스, 인크. 아자벤즈이미다졸 및 ampa 수용체 조절제로서의 이의 용도
US10729680B2 (en) * 2016-01-14 2020-08-04 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines

Also Published As

Publication number Publication date
KR20210097124A (ko) 2021-08-06
AU2019373416A1 (en) 2021-06-10
WO2020087170A1 (fr) 2020-05-07
BR112021008336A2 (pt) 2021-08-03
MX2021005012A (es) 2021-07-21
SG11202104460UA (en) 2021-05-28
CA3118218A1 (fr) 2020-05-07
PH12021550992A1 (en) 2021-10-04
JP2022510501A (ja) 2022-01-26
ECSP21038390A (es) 2021-08-31
CN113454080A (zh) 2021-09-28
EP3873905A1 (fr) 2021-09-08
IL282801A (en) 2021-06-30
CR20210281A (es) 2021-10-25
US20210277002A1 (en) 2021-09-09
EP3873905A4 (fr) 2022-08-17

Similar Documents

Publication Publication Date Title
MA54091A (fr) Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
MA39484A (fr) Indazoles à substituants benzyle utilisés comme inhibiteurs de bub1
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MA50045A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MX2016009403A (es) Compuestos heterociclicos.
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA52648A (fr) Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA50250A (fr) Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
MA40875B1 (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
WO2017053638A8 (fr) Composés et compositions pour le traitement de troubles oculaires
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
WO2017201200A8 (fr) Compositions thérapeutiques contenant des antagonistes de rar-alpha
MA43848A (fr) Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés